Why Teva Pharmaceutical Industries Stock Is Back in Focus

Teva Pharmaceutical Industries (NYSE:TEVA) has moved its anti IL-15 antibody TEV-'408 into a phase 2b trial for nonsegmental vitiligo after phase 1b data suggested repigmentation benefits and a favorable safety profile.

The quarterly subcutaneous dosing schedule and targeted autoimmune mechanism set TEV-'408 apart from existing vitiligo treatments, which could influence how investors think about Teva Pharmaceutical Industries and its longer term pipeline mix.

Teva Pharmaceutical Industries has also drawn fresh attention in the market, with the share price at US$36.77 and a 30 day share price return of 16.51% helping underpin a 1 year total shareholder return of 105.88% as investors weigh the TEV-'408 update alongside the broader branded and generic portfolio.

If you are looking beyond Teva Pharmaceutical Industries for other healthcare related opportunities, this could be a useful moment to scan 44 healthcare AI stocks for fresh ideas in the sector.

Teva Pharmaceutical Industries now has fresh clinical momentum and a strong revenue base above US$17.3b. After a share price that has more than doubled in 1 year, is that strength still available at a reasonable price today?

Most Popular Narrative: 10.1% Undervalued

The most followed narrative on Teva Pharmaceutical Industries puts fair value at $40.90, which sits above the recent $36.77 close and frames the stock as modestly undervalued based on discounted future cash flows and earnings assumptions.

Teva's strategic focus and rapid execution on expanding its innovative branded products (AUSTEDO, AJOVY, UZEDY, and upcoming olanzapine LAI), combined with a late-stage pipeline targeting large patient populations, are expected to influence higher-margin topline growth and a more profitable product mix, affecting gross margin and net earnings.

Curious what sits behind that fair value gap for Teva Pharmaceutical Industries. The narrative leans heavily on earnings, mix shift and a richer profit margin profile. Want to see how those ingredients are stitched together into one valuation story.

Result: Fair Value of $40.90 (UNDERVALUED)

However, Teva Pharmaceutical Industries still carries meaningful risks, including its sizeable debt load and its reliance on a few branded drugs that could face pricing pressure.

Another View On Teva Pharmaceutical Industries Valuation

The first fair value story for Teva Pharmaceutical Industries leans on future earnings and cash flows, yet the current 60.7x P/E is far above the peer average of 18.7x and a fair ratio of 35.6x. That gap points to valuation risk. Could the market already be paying up for the growth narrative?

For a closer look at how those earnings multiples stack up across peers and the fair ratio, it is worth reviewing the detailed breakdown in See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed messages on Teva Pharmaceutical Industries so far. There are clear concerns and also some bright spots that investors are watching closely. If you want to move quickly and shape your own view based on both sides of the story, start with the 3 key rewards and 2 important warning signs

Looking For More Investment Ideas Beyond Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries is only one piece of the puzzle. Use the Simply Wall Street Screener to line up your next ideas before the crowd catches on.

• Target steadier potential returns by scanning 83 resilient stocks with low risk scores that aim to keep big drawdowns in check while still offering room for growth.
• Spot quality at a discount by reviewing 50 high quality undervalued stocks that combine solid fundamentals with prices that may sit below estimated fair value.
• Strengthen your income focus by filtering 10 dividend fortresses built around higher yields that may help support regular cash flow from your portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.